Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

This study is testing a three-drug combination — surufatinib (a targeted drug that cuts off blood supply to tumors), camrelizumab (an immunotherapy drug), and chemotherapy (nab-paclitaxel plus gemcitabine) — as a first-line treatment for people with advanced pancreatic cancer that cannot be removed surgically. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced, locally advanced, or metastatic pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - You have not yet received any systemic treatment for your advanced disease - You have at least one measurable tumor - You are in good physical condition (ECOG score of 0–1) - Your organ function meets the required levels **You may NOT be eligible if...** - You have previously used VEGFR inhibitors or immunotherapy drugs - You have significant heart disease, uncontrolled high blood pressure, or active bleeding - You have HIV, active hepatitis B or C - You have brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.